Petros Grivas, MD, PhD, on Updates in Genitourinary Oncology From ASCO 2021
Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting
Among the numerous trials that were presented, the phase 3 VISION trial (NCT03511664), which examined lutetium-177-PSMA-617 (Lutathera) in patients with metastatic castration-resistant prostate cancer, was particularly important.1 Additionally, the phase 3 KEYNOTE-564 trial (NCT03142334), which examined adjuvant pembrolizumab (Keytruda) in resected renal cell carcinoma (RCC), yielded interesting data, according to Grivas.2
Transcript:
We had the opportunity to see amazing presentations at the ASCO 2021 Virtual Meeting. It is definitely difficult to summarize everything in a few minutes, but definitely the plenary session presentations, [no] doubt, [were important]. The lutetium [prostate-specific membrane antigen; PSMA] data from the randomized clinical trial that Michael J. Morris, MD, [of Memorial Sloan Kettering Cancer Center] presented at the ASCO plenary session [were] definitely very important. It is very likely to be practice changing. Here at Seattle Cancer Care Alliance, we are working on having PSMA-PET scans available for our patients, either for clinical trials or as a standard of care down the road.
It is very likely that this lutetium-177-PSMA-617 radiopharmaceutical is likely to be an approved option down the road. The data from Moore’s [presentation] substantiate that argument. Also very interesting [were the] data from Toni Choueiri, [MD] of Dana-Farber Cancer Institute in the adjuvant setting in patients with resected RCC. [In] adjuvant kidney cancer, pembrolizumab [demonstrated] disease-free survival benefit vs the control group. That is a very important dataset. There was a trend that the overall survival [OS] might also be beneficial, but the OS data were not mature yet. In that particular dataset, we have to wait to see OS in the adjuvant [setting]. The data I’m referring to [are from] the KEYNOTE-564 trial, [which was] also presented [during] the plenary session. We will have to see whether the FDA will review and approve adjuvant pembrolizumab in resected kidney cancer
Reference
- Morris MJ, De Bono JS, Chi KN, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021;39(suppl 15):LBA4. doi:10.1200/JCO.2021.39.15_suppl.LBA4
- Choueiri TK, Quinn DI, Zhang T, et al. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. J Clin Oncol. 2021;36(suppl 15):TPS4599. doi:10.1200/JCO.2018.36.15_suppl.TPS4599
